Tokyo Tape
Sign in
← Fuso Pharmaceutical Industries

Annual report

4538.TEDINET S100OL98
Period2021-04-01 → 2022-03-31
Filed2022-06-29
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 88
MetricValuePeriodScopeSource row
Revenue¥49.6bn2021-04-01 → 2022-03-31StandaloneNet sales
Revenue¥49.3bn2020-04-01 → 2021-03-31StandaloneNet sales
Revenue¥46.9bn2019-04-01 → 2020-03-31dStandaloneNet sales (5-year summary)
Revenue¥46.1bn2018-04-01 → 2019-03-31dStandaloneNet sales (5-year summary)
Revenue¥45.9bn2017-04-01 → 2018-03-31dStandaloneNet sales (5-year summary)
Operating income¥1.9bn2021-04-01 → 2022-03-31StandaloneOperating income
Operating income¥2.4bn2020-04-01 → 2021-03-31StandaloneOperating income
Ordinary income¥2.0bn2021-04-01 → 2022-03-31StandaloneOrdinary income
Ordinary income¥2.2bn2020-04-01 → 2021-03-31StandaloneOrdinary income
Ordinary income¥1.1bn2019-04-01 → 2020-03-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥1.3bn2018-04-01 → 2019-03-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥832m2017-04-01 → 2018-03-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax¥1.9bn2021-04-01 → 2022-03-31StandaloneIncome before income taxes
Profit before tax¥2.3bn2020-04-01 → 2021-03-31StandaloneIncome before income taxes
Net income¥1.5bn2021-04-01 → 2022-03-31StandaloneProfit loss
Net income¥1.6bn2020-04-01 → 2021-03-31StandaloneProfit loss
Net income¥707m2019-04-01 → 2020-03-31dStandaloneNet income loss (5-year summary)
Net income¥894m2018-04-01 → 2019-03-31dStandaloneNet income loss (5-year summary)
Net income¥970m2017-04-01 → 2018-03-31dStandaloneNet income loss (5-year summary)
Total assets¥69.3bnat 2022-03-31StandaloneAssets
Total assets¥69.9bnat 2021-03-31StandaloneAssets
Total assets¥69.2bnat 2020-03-31dStandaloneTotal assets (5-year summary)
Total assets¥71.7bnat 2019-03-31dStandaloneTotal assets (5-year summary)
Total assets¥70.2bnat 2018-03-31dStandaloneTotal assets (5-year summary)
Total liabilities¥34.8bnat 2022-03-31StandaloneLiabilities
Total liabilities¥36.2bnat 2021-03-31StandaloneLiabilities
Net assets / equity¥34.5bnat 2022-03-31StandaloneNet assets
Net assets / equity¥33.7bnat 2021-03-31StandaloneNet assets
Net assets / equity¥32.3bnat 2020-03-31dStandaloneNet assets
Net assets / equity¥32.8bnat 2019-03-31dStandaloneNet assets (5-year summary)
Net assets / equity¥32.6bnat 2018-03-31dStandaloneNet assets (5-year summary)
Cash and deposits¥7.3bnat 2022-03-31StandaloneCash and deposits
Cash and deposits¥7.1bnat 2021-03-31StandaloneCash and deposits
Cash & equivalents¥7.3bnat 2022-03-31StandaloneCash and cash equivalents
Cash & equivalents¥7.1bnat 2021-03-31StandaloneCash and cash equivalents
Cash & equivalents¥7.3bnat 2020-03-31dStandaloneCash and cash equivalents
Cash & equivalents¥4.8bnat 2019-03-31dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥5.5bnat 2018-03-31dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow¥3.5bn2021-04-01 → 2022-03-31StandaloneNet cash provided by used in operating activities
Operating cash flow¥3.2bn2020-04-01 → 2021-03-31StandaloneNet cash provided by used in operating activities
Operating cash flow¥5.7bn2019-04-01 → 2020-03-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow¥2.1bn2018-04-01 → 2019-03-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow¥1.4bn2017-04-01 → 2018-03-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow−¥1.6bn2021-04-01 → 2022-03-31StandaloneNet cash provided by used in investment activities
Investing cash flow−¥978m2020-04-01 → 2021-03-31StandaloneNet cash provided by used in investment activities
Investing cash flow−¥1.5bn2019-04-01 → 2020-03-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥2.4bn2018-04-01 → 2019-03-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥984m2017-04-01 → 2018-03-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow−¥1.7bn2021-04-01 → 2022-03-31StandaloneNet cash provided by used in financing activities
Financing cash flow−¥2.4bn2020-04-01 → 2021-03-31StandaloneNet cash provided by used in financing activities
Financing cash flow−¥1.8bn2019-04-01 → 2020-03-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow−¥313m2018-04-01 → 2019-03-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥69m2017-04-01 → 2018-03-31dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥169.092021-04-01 → 2022-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥183.182020-04-01 → 2021-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥80.592019-04-01 → 2020-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥101.962018-04-01 → 2019-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥109.612017-04-01 → 2018-03-31dStandaloneBasic earnings loss per share (5-year summary)
Dividend per share¥602021-04-01 → 2022-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥602020-04-01 → 2021-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥602019-04-01 → 2020-03-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥802018-04-01 → 2019-03-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥802017-04-01 → 2018-03-31dStandaloneDividend paid per share (5-year summary)
Net assets per share¥3,936.7at 2022-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥3,839.54at 2021-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥3,681.46at 2020-03-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥3,742.48at 2019-03-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥3,711.54at 2018-03-31dStandaloneNet assets per share (5-year summary)
Equity ratio49.8%at 2022-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio48.2%at 2021-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio46.7%at 2020-03-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio45.8%at 2019-03-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio46.4%at 2018-03-31dStandaloneEquity to asset ratio (5-year summary)
ROE4.3%2021-04-01 → 2022-03-31StandaloneRate of return on equity (5-year summary)
ROE4.9%2020-04-01 → 2021-03-31StandaloneRate of return on equity (5-year summary)
ROE2.2%2019-04-01 → 2020-03-31dStandaloneRate of return on equity (5-year summary)
ROE2.7%2018-04-01 → 2019-03-31dStandaloneRate of return on equity (5-year summary)
ROE3.0%2017-04-01 → 2018-03-31dStandaloneRate of return on equity (5-year summary)
Shares issued9,451,169at 2022-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued9,451,169at 2021-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued9,451,169at 2020-03-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued9,451,169at 2019-03-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued9,451,169at 2018-03-31dStandaloneTotal number of issued shares (5-year summary)
Employees1,344at 2022-03-31StandaloneNumber of employees
Employees1,356at 2021-03-31StandaloneNumber of employees
Employees1,352at 2020-03-31dStandaloneNumber of employees
Employees1,347at 2019-03-31dStandaloneNumber of employees
Employees1,366at 2018-03-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 2
SegmentItemPeriodValue
Pharmaceutical Businessreportable segmentemployeesat 2022-03-311288 pure
Real Estate Businessreportable segmentemployeesat 2022-03-311 pure

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,093
ItemContextValueUnit
Salaries sgaPrior1YearDuration_NonConsolidatedMember2437000000JPY
Salaries sgaCurrentYearDuration_NonConsolidatedMember2430000000JPY
Provision for bonuses sgaPrior1YearDuration_NonConsolidatedMember424000000JPY
Provision for bonuses sgaCurrentYearDuration_NonConsolidatedMember402000000JPY
Provision for directors bonuses sgaPrior1YearDuration_NonConsolidatedMember32000000JPY
Provision for directors bonuses sgaCurrentYearDuration_NonConsolidatedMember23000000JPY
Provision for directors retirement benefits sgaPrior1YearDuration_NonConsolidatedMember15000000JPY
Provision for directors retirement benefits sgaCurrentYearDuration_NonConsolidatedMember16000000JPY
Retirement benefit expenses sgaPrior1YearDuration_NonConsolidatedMember299000000JPY
Retirement benefit expenses sgaCurrentYearDuration_NonConsolidatedMember331000000JPY
Depreciation sgaPrior1YearDuration_NonConsolidatedMember487000000JPY
Depreciation sgaCurrentYearDuration_NonConsolidatedMember487000000JPY
Research and development expenses sgaPrior1YearDuration_NonConsolidatedMember1462000000JPY
Research and development expenses sgaCurrentYearDuration_NonConsolidatedMember1442000000JPY
Research and development expenses included in general and administrative expenses and manufacturing cost for current periodPrior1YearDuration_NonConsolidatedMember1462000000JPY
Research and development expenses included in general and administrative expenses and manufacturing cost for current periodCurrentYearDuration_NonConsolidatedMember1442000000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)有価証券報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2022-06-29
Fiscal year cover pageFilingDateInstant
Original text (Japanese)第99期(自　2021年４月１日　至　2022年３月31日)
Company name cover pageFilingDateInstant
Original text (Japanese)扶桑薬品工業株式会社
Company name in english cover pageFilingDateInstantFuso Pharmaceutical Industries, Ltd.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　　戸　田　幹　雄
Address of registered headquarter cover pageFilingDateInstantText · Plus
Telephone number address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)06-6969-1131(代表)
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)取締役総務本部長(兼)経理部長　　髙　橋　貞　雄
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都中央区日本橋本町二丁目４番５号
Telephone number nearest place of contact cover pageFilingDateInstant
Original text (Japanese)03-5203-7101(代表)
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)執行役員営業本部東京第一支店長(兼)東京事務所長松　井　幸　信
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE00953
Fund codeFilingDateInstant－
Security codeFilingDateInstant45380
Filer name in japaneseFilingDateInstant
Original text (Japanese)扶桑薬品工業株式会社
Filer name in englishFilingDateInstantFuso Pharmaceutical Industries, Ltd.
Fund name in japaneseFilingDateInstant－
Fund name in englishFilingDateInstant－
Cabinet office ordinanceFilingDateInstant
Original text (Japanese)企業内容等の開示に関する内閣府令
Document typeFilingDateInstant
Original text (Japanese)第三号様式
Accounting standardsFilingDateInstantJapan GAAP
Whether consolidated financial statements are preparedFilingDateInstantfalse
Industry code when consolidated financial statements are prepared in accordance with industry specific regulationsFilingDateInstant－
Industry code when financial statements are prepared in accordance with industry specific regulationsFilingDateInstantcte
Current fiscal year start dateFilingDateInstant2021-04-01
Current period end dateFilingDateInstant2022-03-31
Type of current periodFilingDateInstantFY
Current fiscal year end dateFilingDateInstant2022-03-31
Previous fiscal year start dateFilingDateInstant2020-04-01
Comparative period end dateFilingDateInstant2021-03-31

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 13 of 13 passed
balance sheet identitynon_consolidated 2021-03-31pass
balance sheet identitynon_consolidated 2022-03-31pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2020-03-31pass
statement vs summary · net assetsnon_consolidated 2021-03-31pass
statement vs summary · net assetsnon_consolidated 2022-03-31pass
statement vs summary · operating cash flownon_consolidated 2020-04-01/2021-03-31pass
statement vs summary · operating cash flownon_consolidated 2021-04-01/2022-03-31pass
statement vs summary · revenuenon_consolidated 2020-04-01/2021-03-31pass
statement vs summary · revenuenon_consolidated 2021-04-01/2022-03-31pass
statement vs summary · total assetsnon_consolidated 2021-03-31pass
statement vs summary · total assetsnon_consolidated 2022-03-31pass